

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

February 16, 2006
(Date of earliest event reported)

**LABORATORY CORPORATION OF
AMERICA HOLDINGS**

(Exact Name of Registrant as Specified in its Charter)

DELAWARE

(State or other jurisdiction
of Incorporation)

1-11353

(Commission
File Number)

13-3757370

(I.R.S. Employer
Identification No.)

**358 SOUTH MAIN STREET,
BURLINGTON, NORTH CAROLINA**

(Address of principal executive offices)

27215

(Zip Code)

336-229-1127

(Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. Regulation FD Disclosure

Summary information of the Company dated February 16, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Laboratory Corporation of America Holdings
(Registrant)


Date: February 16, 2006

By: /s/Bradford T. Smith
Bradford T. Smith, Executive Vice President
and Secretary



This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect the Company's financial results is included in the Company's Form 10-K for the year ended December 31, 2004, and subsequent filings, and will be available in the Company's Form 10-K for the year ended December 31, 2005, when filed.

The Clinical Laboratory Testing Market - \$40 billion Annually




- Independent clinical lab share is \$16 billion
- Represents 2% to 3% of all health care spending
- Influences /directs approximately 80% of health care spending
- Rapidly evolving technology, emphasis on preventative medicine and aging of population are all driving growth
- Has grown at a CAGR of between 5% and 6%

Source: Company estimates, industry reports and 2004 revenue for LabCorp.

Profile of LabCorp

- A leader in the esoteric and genomic testing market and second-largest clinical laboratory company in North America
- Offers a broad range of routine and esoteric/genomic tests
- Conducts testing on more than 360,000 specimens daily
- Provides lab services to physicians and other health care providers
- Approximately 24,000 employees nationwide

Primary Testing Locations




LabCorp's Investment and Performance Fundamentals

- History of Strong Financial Performance
- Significant Cash Generator
- Industry leading EBITDA margins
- Strong Balance Sheet
- Investment Grade Credit Ratings

Net Sales (in millions)



EBITDA Margin



EPS



(1) Excluding the \$0.09 per diluted share impact in 2005 of restructuring and other special charges, and a non-recurring investment loss.

Operating Cash Flow (in millions)



(1) Includes approximately \$50 million of benefit from one-time tax credits recorded in 2003.

LabCorp's Strategy

To **lead** the industry in achieving long-term **growth and profitability** by strengthening our **nationwide core testing** business and expanding our **higher-growth, higher-value esoteric and genomic businesses.**

Strategic Focus Areas

Scientific Leadership

- Licensing/partnerships
- Cancer
- Acquisitions

Managed Care

- Reduce leakage
- Appropriate prices
- Value of new lab tests

Customer Retention

- Specimen tracking
- Customer connectivity
- Report improvement
- Call center consolidation

Fourth Quarter Results (in millions, except per share data)

	<u>12/31/04</u>	<u>12/31/05</u>	<u>+/(-)</u>
Revenue	\$766.5	\$822.3	7.3%
EBITDA (1)	\$185.0	\$199.5	7.8%
EBITDA Margin	24.1%	24.3%	20 bp
Diluted EPS (2)	\$0.58	\$0.67	15.5%

(1) For definition of EBITDA and a reconciliation to the most comparable measure under Generally Accepted Accounting Principles, see Company's 4th quarter 2005 earnings release furnished on Form 8-K on February 16, 2006.

(2) Excluding \$0.03 per diluted share impact of restructuring and other special charges in the fourth quarter of 2005.

Full-Year Results (in millions, except per share data)

	12/31/04	12/31/05	+/(-)
Revenue	\$3,084.8	\$3,327.6	7.9%
EBITDA ⁽¹⁾	\$787.8	\$845.8	7.4%
EBITDA Margin	25.5%	25.4%	(10 bp)
Diluted EPS ⁽²⁾	\$2.45	\$2.80	14.3%

(1) For definition of EBITDA and a reconciliation to the most comparable measure under Generally Accepted Accounting Principles, see Company's 4th quarter 2005 earnings release furnished on Form 8-K on February 16, 2006.

(2) Excluding the \$0.09 per diluted share impact in 2005 of restructuring and other special charges, and a non-recurring investment loss.

2005 Full-Year Financial Achievements

- Diluted EPS of \$2.80 ⁽¹⁾
- EBITDA margin of 25.4% of sales
- Operating cash flow of \$574.2 million
- Increased revenues 7.9% (1.1% volume; 6.8% price)
- Repurchased approximately \$589 million of LabCorp stock
- Completed US LABS and Esoterix acquisitions

(1) Excluding the \$0.09 per diluted share impact of restructuring and other special charges, and a non-recurring investment loss.

Price & Volumes: Trends by Payor Type

Financial Performance

	2003		2004		2005	
	PPA \$	Accessions millions	PPA \$	Accessions millions	PPA \$	Accessions millions
Client (Physicians)	\$27.07	31.7	\$26.61	32.7	\$29.11	32.1
Patient	118.48	2.5	123.59	2.5	135.12	2.2
Third Party (MC/MD/Insurance)	34.25	18.1	34.84	18.9	38.49	19.6
Managed Care						
• Capitated	9.95	12.9	10.36	12.8	10.60	12.9
• Fee for service	45.68	22.7	46.01	24.2	47.36	25.3
Total	32.74	35.6	33.67	37.0	34.98	38.2
LabCorp Total	\$33.43	87.9	\$33.86	91.1	\$36.12	92.1

Financial Performance

Revenue Analysis by Business Area

	YTD DEC 2004				YTD DEC 2005				05 vs 04
	Revenue \$Million	Accns 000	% Accns to total	PPA \$	Revenue \$Million	Accns 000	% Accns to total	PPA \$	PPA Incr/(Decr)
Genomic	\$294.4	2,510.3	2.8%	\$117.27	\$331.7	2,868.0	3.1%	\$115.65	(1.4%)
Identity/Gene Probes	168.9	3,822.1	4.1%	44.20	173.5	3,861.3	4.2%	44.93	1.7%
All Genomic	463.3	6,332.4	6.9%	73.16	505.2	6,729.3	7.3%	75.07	2.6%
Other Esoteric	298.2	7,211.1	7.9%	41.35	340.9	8,175.1	8.9%	41.69	0.8%
Histology	205.0	2,255.6	2.5%	90.89	283.7	2,406.1	2.6%	117.92	29.7%
All Genomic/ Esoteric Core	966.5	15,799.1	17.3%	61.18	1,129.8	17,310.5	18.8%	65.26	6.7%
	2,118.3	75,318.5	82.7%	28.12	2,197.8	74,809.8	81.2%	29.38	4.5%
Total	\$3,084.8	91,117.6	100.0%	\$33.86	\$3,327.6	92,120.3	100.0%	\$36.12	6.7%

Free Cash Flow Investment Strategy

- Acquisitions
- Stock repurchase program
- Retain flexibility in utilizing remaining cash

2006 Financial Guidance

Before the required change in accounting for stock based compensation, guidance for 2006 is as follows and assumes completion of the \$500 million share repurchase authorization announced on December 7, 2005:

- **Revenue growth of approximately 6.5% to 7.5% compared to 2005.**
- **EBITDA margins of 26.0 to 26.5% of revenues.**
- **Diluted EPS in the range of \$3.15 to \$3.25.**
- **Operating cash flow of between \$600 and \$620 million.**
- **Capital expenditures of between \$100 and \$115 million.**
- **Net interest expense of approximately \$47 million.**
- **Bad debt rate of approximately 5.3% of sales.**

We estimate that the implementation of the required change in accounting for stock based compensation will have an EBITDA impact of approximately \$25 million and a diluted EPS impact of approximately \$0.11.

Other Financial Information

For the Quarter and Year Ended December 31, 2005

(\$ in millions)					YTD
	Q1	Q2	Q3	Q4	2005
Depreciation	\$ 23.2	\$ 24.1	\$ 24.2	\$ 25.7	\$ 97.2
Amortization	\$ 12.1	\$ 13.1	\$ 13.1	\$ 13.1	\$ 51.4
Capital expenditures	\$ 25.5	\$ 20.2	\$ 25.7	\$ 22.2	\$ 93.6
Cash flows from operations	\$ 154.5	\$ 86.5	\$ 172.0	\$ 161.2	\$ 574.2
Bad debt as a percentage of sales	5.5%	5.3%	5.3%	5.3%	5.4%
Effective interest rate on debt:					
Zero coupon-subordinated notes	2.00%	2.00%	2.00%	2.00%	2.00%
5 1/2% Senior Notes (including effect of interest rate swap)	5.38%	5.38%	5.38%	5.38%	5.38%
5 5/8% Senior Notes	--	--	--	5.75%	5.75%
Revolving credit facility (weighted average)	3.31%	3.62%	4.34%	4.87%	4.87%
Days sales outstanding	55	55	55	54	54



LabCorp
Laboratory Corporation of America

